Kwality Pharmaceuticals Intrinsic Value
Kwality Pharmaceuticals intrinsic value. Kwality Pharmaceuticals (KPL) median intrinsic value is ₹1457.68 from 9 valuation models (range ₹729–₹2146), vs current price ₹3644.20 — -60.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Read KPL dividend history for the complete payout history and dividend yield track record.
KPL Valuation Methods Summary — DCF, Graham Number & P/E
Kwality Pharmaceuticals intrinsic value across 9 models vs current price ₹3644.20 — upside/downside and value range per method. For current market price and key ratios, visit Kwality Pharmaceuticals screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹2146.32 | ₹1717.06 - ₹2575.58 | -41.1% | EPS: ₹97.56, Sector P/E: 22x |
| Book Value Method | asset | ₹728.84 | ₹655.96 - ₹801.72 | -80.0% | Book Value/Share: ₹330.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1264.00 | ₹1137.60 - ₹1390.40 | -65.3% | Revenue/Share: ₹632.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1600.00 | ₹1440.00 - ₹1760.00 | -56.1% | EBITDA: ₹160.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹1457.68 | ₹1166.14 - ₹1749.22 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹1093.26 | ₹983.93 - ₹1202.59 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹1507.30 | ₹1356.57 - ₹1658.03 | -58.6% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹1822.10 | ₹1639.89 - ₹2004.31 | -50.0% | ROE: 30.3%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹1093.26 | ₹983.93 - ₹1202.59 | -70.0% | EPS: ₹97.56, BVPS: ₹330.00 |
KPL Intrinsic Value vs Market Price — All Valuation Models
Kwality Pharmaceuticals fair value range ₹729–₹2146 vs current market price ₹3644.20 across 9 valuation models. Compare with KPL DCF valuation to assess whether the stock is under or overvalued.
KPL Intrinsic Value Analysis — Undervalued or Overvalued?
Kwality Pharmaceuticals median intrinsic value ₹1457.68, current price ₹3644.20 — Trading Above Calculated Value by 60.0%, margin of safety -100.0%.
What is the intrinsic value of KPL?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Kwality Pharmaceuticals (KPL) is ₹1457.68 (median value). With the current market price of ₹3644.20, this represents a -60.0% variance from our estimated fair value.
The valuation range spans from ₹728.84 to ₹2146.32, indicating ₹728.84 - ₹2146.32.
Is KPL undervalued or overvalued?
Based on our multi-method analysis, Kwality Pharmaceuticals (KPL) appears to be trading above calculated value by approximately 60.0%.
KPL Financial Health — Key Ratios vs Industry Benchmarks
Kwality Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 10.97 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 30.3% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 25.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.07x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
KPL Cash Flow Quality — Operating & Free Cash Flow
Kwality Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹17 Cr | ₹-1 Cr | Positive Operating Cash Flow | 6/10 |
| March 2025 | ₹53 Cr | ₹39 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹43 Cr | ₹30 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹41 Cr | ₹17 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹61 Cr | ₹30 Cr | Positive Free Cash Flow | 7/10 |